You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

~ Buy the CYSVIEW KIT (hexaminolevulinate hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CYSVIEW KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cysview Kit, and when can generic versions of Cysview Kit launch?

Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-nine patent family members in seventeen countries.

The generic ingredient in CYSVIEW KIT is hexaminolevulinate hydrochloride. One supplier is listed for this compound. Additional details are available on the hexaminolevulinate hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Cysview Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CYSVIEW KIT?
  • What are the global sales for CYSVIEW KIT?
  • What is Average Wholesale Price for CYSVIEW KIT?
Drug patent expirations by year for CYSVIEW KIT
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CYSVIEW KIT
Generic Entry Date for CYSVIEW KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SOLUTION;INTRAVESICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CYSVIEW KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dr. Te VuongPhase 2
KARL STORZ Endoscopy-America, Inc.Phase 2
KARL STORZ Endoscopy-America, Inc.Phase 3

See all CYSVIEW KIT clinical trials

US Patents and Regulatory Information for CYSVIEW KIT

CYSVIEW KIT is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CYSVIEW KIT is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting CYSVIEW KIT

Neoadjuvant therapy for bladder cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

Method of photodynamic therapy (PDT) for bladder cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

Neoadjuvant therapy for bladder cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CYSVIEW KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 ⤷  Sign Up ⤷  Sign Up
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 ⤷  Sign Up ⤷  Sign Up
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 ⤷  Sign Up ⤷  Sign Up
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CYSVIEW KIT

When does loss-of-exclusivity occur for CYSVIEW KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 16372573
Patent: Neoadjuvant therapy for bladder cancer
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2018012009
Patent: terapia neoadjuvante para câncer de bexiga
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 08551
Patent: TRAITEMENT NEOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
Estimated Expiration: ⤷  Sign Up

China

Patent: 8601836
Patent: 用于膀胱癌的新辅助疗法 (Neoadjuvant therapy for bladder cancer)
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 89717
Patent: TRAITEMENT NÉOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 26086
Estimated Expiration: ⤷  Sign Up

Patent: 18537514
Patent: 膀胱癌のための術前補助療法
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 18124868
Patent: НЕОАДЪЮВАНТНАЯ ТЕРАПИЯ ДЛЯ РАКА МОЧЕВОГО ПУЗЫРЯ
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 180094987
Patent: 방광암에 대한 신보조 요법
Estimated Expiration: ⤷  Sign Up

United Kingdom

Patent: 1522309
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CYSVIEW KIT around the world.

Country Patent Number Title Estimated Expiration
Austria 202076 ⤷  Sign Up
South Korea 100444007 ⤷  Sign Up
Russian Federation 2018123834 СПОСОБ ФОТОДИНАМИЧЕСКОЙ ТЕРАПИИ (ФДТ) ДЛЯ РАКА МОЧЕВОГО ПУЗЫРЯ ⤷  Sign Up
Austria 228018 ⤷  Sign Up
Czech Republic 9702848 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CYSVIEW KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0820432 SPC/GB02/038 United Kingdom ⤷  Sign Up PRODUCT NAME: METHYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY METHYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 16338 20010615; UK PL18952/0002 20020408
0820432 07C0010 France ⤷  Sign Up PRODUCT NAME: AMINOLEVULINATE DE METHYLE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 30885 20060919; FIRST REGISTRATION: SE - 16338 20010615
0820432 SPC/GB05/044 United Kingdom ⤷  Sign Up PRODUCT NAME: HEXYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY HEXYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 19227 20040917; UK PL 18952/0003 20050714
0820432 05C0042 France ⤷  Sign Up PRODUCT NAME: HEXYL AMINOLEVULINATE; NAT. REGISTRATION NO/DATE: NL 30979 20050812; FIRST REGISTRATION: SE - 19 227 20040917
0820432 SPC024/2002 Ireland ⤷  Sign Up SPC024/2002: 20041230, EXPIRES: 20160614
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.